Artiva Biotherapeutics (NASDAQ:ARTV) Given "Buy" Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV - Free Report) in a research report released on Tuesday morning,Benzinga reports. They currently have a $23.00 price objective on the stock.

Several other research firms also recently issued reports on ARTV. Cantor Fitzgerald dropped their price target on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a research note on Tuesday, March 25th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday, March 26th. Finally, Wedbush reaffirmed an "outperform" rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $20.40.

Artiva Biotherapeutics Trading Up 7.6 %

Shares of Artiva Biotherapeutics stock traded up $0.14 during midday trading on Tuesday, hitting $1.98. 180,943 shares of the company traded hands, compared to its average volume of 170,216. Artiva Biotherapeutics has a 12 month low of $1.78 and a 12 month high of $17.31. The firm's fifty day moving average price is $3.90 and its 200-day moving average price is $8.45.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ARTV. State Street Corp bought a new position in Artiva Biotherapeutics during the third quarter valued at about $1,337,000. Geode Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at $4,774,000. Barclays PLC bought a new position in shares of Artiva Biotherapeutics in the third quarter valued at approximately $304,000. BNP Paribas Financial Markets purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at $42,000. Finally, JPMorgan Chase & Co. bought a new position in Artiva Biotherapeutics in the 3rd quarter worth about $166,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.